Recursion Pharmaceuticals (RXRX) Times Interest Earned (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Times Interest Earned came in at -$29.77 in Q1 2026, up 18.08% YoY from -$25.21 in Q1 2025, and down 346.14% on a QoQ basis from $12.1 in Q4 2025.
Recursion Pharmaceuticals (RXRX) Times Interest Earned (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Times Interest Earned data on file, last reported at -$29.77 in Q1 2026.
- Quarterly Times Interest Earned rose 18.08% year-over-year to -$29.77 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$147.13 (down 145.15% YoY) and the FY2025 annual result came in at -$0.97, up 5.21% from the prior year.
- Times Interest Earned eased to -$29.77 in Q1 2026, from $12.1 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $23.84 in Q4 2023 to a low of -$4813.3 in Q3 2022.
- A 5-year average of -$1465.2 and a median of -$54.81 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned slumped 28790.39% — and 2023, when it surged 376.3%.
- Tracing RXRX's Times Interest Earned over 5 years: stood at -$8.63 in 2022, then surged by 376.3% to $23.84 in 2023, then sank by 329.91% to -$54.81 in 2024, then jumped by 122.07% to $12.1 in 2025, then sank by 346.14% to -$29.77 in 2026.
- The last three Times Interest Earned figures came in at -$29.77 (Q1 2026), $12.1 (Q4 2025), and -$8.51 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -436.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -436.79 |
| Mar 31, 2026 | -29.77 |
| Dec 31, 2025 | 12.10 |
| Sep 30, 2025 | -8.51 |
| Jun 30, 2025 | -6.82 |
| Mar 31, 2025 | -36.35 |
| Dec 31, 2024 | -54.81 |
| Sep 30, 2024 | -177.86 |
| Jun 30, 2024 | -255.19 |
| Mar 31, 2024 | -24.36 |
| Dec 31, 2023 | 23.84 |
| Sep 30, 2023 | -3,982.00 |
| Jun 30, 2023 | -3,142.88 |
| Mar 31, 2023 | -3,677.11 |
| Dec 31, 2022 | -8.63 |
| Sep 30, 2022 | -4,813.31 |
| Jun 30, 2022 | -4,727.93 |
| Mar 31, 2022 | -3,998.64 |
| Dec 31, 2021 | -4,330.67 |
| Sep 30, 2021 | -210.92 |